Rafferty Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Rafferty Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.46M	Sell	115,480 -61,699	-35%	-$700K	0.01%	674
2025 Q4	$1.45M	Buy	177,179 +91,587	+107%	+$1.05M	0.01%	724
2025 Q3	$1.03M	Buy	85,592 +42,948	+101%	+$452K	﹤0.01%	787
2025 Q2	$433K	Sell	42,644 -34,780	-45%	-$233K	﹤0.01%	913
2025 Q1	$432K	Buy	77,424 +26,032	+51%	+$228K	﹤0.01%	898
2024 Q4	$415K	Sell	51,392 -13,193	-20%	-$121K	﹤0.01%	948
2024 Q3	$662K	Sell	64,585 -51,623	-44%	-$510K	﹤0.01%	879
2024 Q2	$822K	Buy	116,208 +5,062	+5%	+$45.3K	﹤0.01%	858
2024 Q1	$1.53M	Buy	+111,146	New	+$1.32M	0.01%	753
2022 Q1	–	Sell	-68,423	Closed	-$1.01M	–	1300
2021 Q4	$1.01M	Buy	68,423 +37,112	+119%	+$579K	0.01%	857
2021 Q3	$655K	Sell	31,311 -16,323	-34%	-$331K	﹤0.01%	983
2021 Q2	$843K	Sell	47,634 -19,730	-29%	-$432K	0.01%	965
2021 Q1	$1.65M	Buy	+67,364	New	+$2.13M	0.01%	674

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Rafferty Asset Management's ORIC Position: Q1 2026 in Review

Rafferty Asset Management reduced its Oric Pharmaceuticals (ORIC) stake by 35% in Q1 2026, selling an estimated $700K and leaving 115,480 shares worth $1.46M. The position accounts for 0.01% of the portfolio, ranked #674.

Rafferty Asset Management first reported a position in ORIC in Q1 2021 and has held it in 13 quarters since. The position peaked at $1.65M in Q1 2021. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

Rafferty Asset Management held 115,480 shares of Oric Pharmaceuticals worth $1.46M as of Q1 2026.
Rafferty Asset Management sold 61,699 Oric Pharmaceuticals shares in Q1 2026, an estimated $700K.
Oric Pharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #674 holding.
Rafferty Asset Management first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 13 quarters since.
Rafferty Asset Management's Oric Pharmaceuticals position peaked at $1.65M in Q1 2021.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.